ADPT — Adaptive Biotechnologies Share Price
0.000.00%
Last trade - 00:00- $1.17bn
- $1.08bn
- $178.96m
- 58
- 12
- 100
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.79 | ||
| Price to Tang. Book | 14.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.83% | ||
| Return on Equity | -62.41% | ||
| Operating Margin | -90.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 98.38 | 154.34 | 185.31 | 170.28 | 178.96 | 212.65 | 259.4 | 16.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Directors
- Chad Robins CHM (46)
- Julie Rubinstein PRE (49)
- Harlan Robins CFD (48)
- Chad Cohen CFO (46)
- Mark Adams COO (54)
- Francis Lo CHO (40)
- Stacy Taylor SVP (61)
- Susan Bobulsky SVP (40)
- Jyoti Palaniappan SVP (46)
- Henning Thorsen SVP (55)
- Nitin Sood CCO
- Lance Baldo OTH (48)
- Sharon Benzeno OTH (47)
- Peter Neupert LED (65)
- Kevin Conroy IND (55)
- Michelle Griffin IND (55)
- Robert Hershberg IND (57)
- Katey Owen IND (52)
- Michael Pellini IND (55)
- Leslie Trigg IND (50)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 8th, 2009
- Public Since
- June 27th, 2019
- No. of Shareholders
- 73
- No. of Employees
- 619
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 148,582,201
- Address
- 1165 Eastlake Ave E, SEATTLE, 98109
- Web
- https://www.adaptivebiotech.com
- Phone
- +1 2066590067
- Contact
- Karina Calzadilla
- Auditors
- Ernst & Young LLP
Upcoming Events for ADPT
Q1 2025 Adaptive Biotechnologies Corp Earnings Call
Adaptive Biotechnologies Corp Annual Shareholders Meeting
Q2 2025 Adaptive Biotechnologies Corp Earnings Release
Similar to ADPT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Adaptive Biotechnologies share price?
As of Today at 19:03 UTC, shares in Adaptive Biotechnologies are trading at $7.90. This share price information is delayed by 15 minutes.
How has the Adaptive Biotechnologies share price performed this year?
Shares in Adaptive Biotechnologies last closed at $7.90 and the price had moved by +202.68% over the past 365 days. In terms of relative price strength the Adaptive Biotechnologies share price has outperformed the S&P500 Index by +179.39% over the past year.
What are the analyst and broker recommendations for Adaptive Biotechnologies?
The overall consensus recommendation for Adaptive Biotechnologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Adaptive Biotechnologies dividend yield?
Adaptive Biotechnologies does not currently pay a dividend.
Does Adaptive Biotechnologies pay a dividend?
Adaptive Biotechnologies does not currently pay a dividend.
When does Adaptive Biotechnologies next pay dividends?
Adaptive Biotechnologies does not currently pay a dividend.
How do I buy Adaptive Biotechnologies shares?
To buy shares in Adaptive Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adaptive Biotechnologies?
As of the previous close price of $7.90, shares in Adaptive Biotechnologies had a market capitalisation of $1.17bn.
Where are Adaptive Biotechnologies shares listed?
Here are the trading details for Adaptive Biotechnologies:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ADPT
What kind of share is Adaptive Biotechnologies?
Based on an overall assessment of its quality, value and momentum Adaptive Biotechnologies is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adaptive Biotechnologies share price forecast for 2025?
The analyst consensus target price for shares in Adaptive Biotechnologies is $9.83. That is 24.43% above the last closing price of $7.90.
Analysts covering Adaptive Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -$0.92 for the next financial year.
Find out moreWhat is the trend in the Adaptive Biotechnologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptive Biotechnologies. Over the past six months, its share price has outperformed the S&P500 Index by +87.11%.
As of the last closing price of $7.90, shares in Adaptive Biotechnologies were trading +30.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adaptive Biotechnologies PE Ratio?
The Adaptive Biotechnologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adaptive Biotechnologies?
Adaptive Biotechnologies' management team is headed by:
- Chad Robins - CHM
- Julie Rubinstein - PRE
- Harlan Robins - CFD
- Chad Cohen - CFO
- Mark Adams - COO
- Francis Lo - CHO
- Stacy Taylor - SVP
- Susan Bobulsky - SVP
- Jyoti Palaniappan - SVP
- Henning Thorsen - SVP
- Nitin Sood - CCO
- Lance Baldo - OTH
- Sharon Benzeno - OTH
- Peter Neupert - LED
- Kevin Conroy - IND
- Michelle Griffin - IND
- Robert Hershberg - IND
- Katey Owen - IND
- Michael Pellini - IND
- Leslie Trigg - IND